How may targeted proteomics complement genomic data in breast cancer

摘要: Introduction: Breast cancer (BC) is the most common female in world and was recently deconstructed different molecular entities. Although of recent assays to characterize tumors at level are genomic-based, proteins actual executors cellular functions represent vast majority targets for anticancer drugs. Accumulated data has demonstrated an important quantitative qualitative discrepancies between genomic/transcriptomic alterations their protein counterparts, mostly related large number post-translational modifications. Areas covered: This review will present novel proteomics technologies such as Reverse Phase Protein Array (RPPA) or mass-spectrometry (MS) based approaches that have emerged could progressively replace old-fashioned methods (e.g. immunohistochemistry, ELISA, etc.) validate diagnostic, prognostic predictive biomarkers, eventually monitor them routine practice. Expert commentary: These targeted proteomic approaches, able complement genomic BC more precisely, permit go through a personalized treatment each patient tumor.